Seconda edizione dell’ASCO-AIOM International Clinical Research Course: come sempre grande partecipazione ed entusiasmo. #ASCO #AIOM ASCO

What inspiring and educational lessons by Ian Tannock and Matt Sydes ! Thanks to AIOM and ASCO for this opportunity ! #clinicalresearchcourse

🔥PLENARY Session #ASCO24🔥 Perioperative chemotherapy (FLOT) to neoadjuvant chemoradiation (CROSS) in patients with adenocarcinoma of the esophagus 🔎 ESOPEC phase III trial, 438 patients 👉R0 180 vs 171 👉pCR 17 vs 10% 👉mOS 66 vs 37 mo 👉3yr OS: 57.4 vs 50.7% 🧐FLOT improves

The best way to start #ESMOGI24 with the keynote lecture on KRAS by Prof. Corcoran! ESMO - Eur. Oncology

Oustanding presentation by Myriam Chalabi on IO for MMR CRC! #ESMOGI24 ESMO - Eur. Oncology

What an honour to hear Prof.Salah-Eddin Al-Batran talk about neoadjuvant treatment in GC ! #neoadjuvantpro #ESMOGI24 ESMO - Eur. Oncology

So grateful and excited to have the opportunity to present at #ESMOGI24 our prospective study on the prognostic impact of mutKRAS cftDNA in BR and LA PDAC ! ESMO - Eur. Oncology

What a beautiful session on oesophago-gastric cancer this morning at #ESMOGI24! Totally inspiring to listen to @FlorianLordick and Lizzy Smyth! ESMO - Eur. Oncology

A priviledge to be part of this team! 🚀

#ESMOGI24 has been incredible! ESMO - Eur. Oncology

Our last paper…fantastic international collaboration -CisGem durvalumab in BTC patients -666 patients: median OS of 15.1 months and median PFS of 8.2 months -The results confirmed the results achieved in the TOPAZ-1 trial ejcancer.com/article/S0959-…

Can we rely on peritoneal specimens for PD-L1 assessment? 🧐 The spatial and temporal heterogeneity of PD-L1 expression in mGEA is a critical issue! Our paper now online on ESMO Gastrointestinal Oncology 👇🏼 sciencedirect.com/science/articl…

So proud of my talented friend Paolo Ciracì who has just presented the phase 1 TriComB study! 🚀 #AIOM24

Trastuzumab Deruxtecan or Ramucirumab plus Paclitaxel in Gastric Cancer NEJM doi.org/10.1056/NEJMoa… 👉Trastuzumab deruxtecan significantly improved overall survival than ramucirumab paclitaxel 🧐Looking forward to the 1st line trials ESMO - Eur. Oncology

Durvalumab + FLOT in resectable GC/GEJ cancer #ASCO25 Plenary session 🔎MATTERHORN 👉mEFS n.r. vs 32.8, HR 0.71 👉mDFS n.r. vs 39.8 mo 👉OS n.r. in both arms, HR 0.78, not (yet) significant 👉pCR 19 vs 7% 🧐 Finally, ICI arrived in the peri-operative setting ESMO - Eur. Oncology

Negative impact of corticosteroid use on outcome in patients with advanced BTCs treated with cisplatin, gemcitabine, and durvalumab: A large real‐life worldwide population onlinelibrary.wiley.com/doi/10.1002/ij…